Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The financial performance shows strong year-over-year growth in revenue, net income, adjusted EBITDA, and operating cash flow, indicating effective management and operational efficiency. Despite the lack of discussion on strategic initiatives or risks, the financial metrics suggest a positive outlook, likely leading to a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue $125.3 million, up 18% year-over-year, driven by increased adoption of our platform by healthcare professionals and expanded enterprise partnerships.
Net Income $30.7 million, representing a 25% increase year-over-year, attributed to operational efficiencies and cost management.
Adjusted EBITDA $45.2 million, up 20% year-over-year, due to higher revenue and disciplined expense control.
Operating Cash Flow $50.1 million, a 22% increase year-over-year, reflecting strong collections and improved working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brian Peterson
CEO Chairperson
Canaccord Genuity
Chairperson PM
Cherny Leerink
Close Canaccord
Craig Hettenbach
Division Anderson
Division Cherny
Division Close
Division Craig
Division Glen
Division Ladies
Division Roman
Division Ryan
Division Scott
EDT Brian
Genuity Corp
Glen Santangelo
LLC Research
PM EDT
Peterson Raymond
Raymond Associates
Relations Jeffrey
Relations disclosure
Roman Goldman
Ryan Halsted
Ryan MacDonald
Santangelo Barclays
Scott Schoenhaus
conference Vice
result
website
DOCS Transcript
Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
Positive5-14
The financial performance shows strong year-over-year growth in revenue, net income, adjusted EBITDA, and operating cash flow, indicating effective management and operational efficiency. Despite the lack of discussion on strategic initiatives or risks, the financial metrics suggest a positive outlook, likely leading to a stock price increase of 2% to 8% over the next two weeks.
Novo Nordisk A/S (NOVO:CA) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call summary indicates a generally positive outlook. The financial performance shows growth in revenue and EBITDA margins, driven by a strong pharma business and AI investments. However, there is some uncertainty in market conditions affecting client budgets. The Q&A section reveals management's confidence in product differentiation and market expansion strategies, despite competitive pressures. The company's strategic investments in AI and marketing, along with optimistic revenue and EBITDA guidance, suggest a positive sentiment. Despite some uncertainties, the overall tone is optimistic, leading to a positive prediction for stock price movement.
Doximity, Inc. (DOCS) Q3 2026 Earnings Call Transcript
Positive2-5
The earnings call summary indicates strong financial performance with significant growth in the pharma business and AI integration. Despite some policy uncertainty affecting client budgets, the company's strategic focus on AI and integrated offerings, along with a high adjusted EBITDA margin, suggests a positive outlook. The Q&A section supports this with plans for AI product launches and expected growth in fiscal 2027. While there are concerns about budget delays, the overall sentiment is positive, indicating a likely stock price increase.
Doximity, Inc. (DOCS) Q2 2026 Earnings Call Transcript
Positive11-6
The earnings call reveals strong financial performance with a 56% EBITDA margin and 15% revenue growth guidance. Product development is promising with AI investments and Pathway acquisition. Market strategy is robust, focusing on AI and health systems. Expenses are controlled with margins expected to remain stable. Shareholder return is not explicitly mentioned, but positive cash flow is anticipated. Q&A insights show optimism in AI and integrated programs, despite some uncertainties in policy impacts. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.
DOCS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
